Clinical Trials Sponsored by Bayer/Onyx

Total 2517 results

Bayer
Onyx Therapeutics, Inc.

Completed

Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of Sorafenib and Eribulin in Combination

Neoplasms

Germany, France
Bayer
Onyx Therapeutics, Inc.

Completed

Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

Breast Cancer

Spain, Ireland, Japan, Russian Federation, United States, Australia, Austria, Czechia, Belgium, China, Germany, Hungary, Israel, South Africa, United Kingdom, France, Greece, Puerto Rico, Italy, Canada, Poland, Sweden, Argentina
Case Comprehensive Cancer Center
Bayer; Onyx Therapeutics, Inc.

Terminated

Pilot Study Sorafenib as Bridge to Orthotopic Liver Transplantation (OLT)

Carcinoma, Hepatocellular

United States
M.D. Anderson Cancer Center
Bayer; Celgene; Onyx Therapeutics, Inc.

Completed

Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic Syndrome

Leukemia

United States
St. Jude Children's Research Hospital
National Cancer Institute (NCI); Bayer/Onyx

Completed

Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Myelodysplastic/Myeloproliferative Neoplasms | Biphenotypic Leukemia | Infantile Leukemia (Both AML and ALL)

United States
Amgen
Onyx Therapeutics, Inc.

Completed

Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma

Relapsed and Refractory Multiple Myeloma

China
Yale University
Onyx Therapeutics, Inc.

Completed

The Effect of Sorafenib on Portal Pressure

Clinically Significant Portal Hypertension

United States
ONY

Completed

Comparison of Aerosol Delivery of Infasurf to Usual Care in Spontaneously Breathing RDS Patients

Respiratory Distress Syndrome

United States
Emory University
Onyx Therapeutics, Inc.

Terminated

Study of Carfilzomib in Combination w/Dexamethasone in Patients w/Newly Diagnosed Multiple Myeloma

Multiple Myeloma

United States
University Hospital, Toulouse
Celgene; Onyx Therapeutics, Inc.

Unknown

Front-line Therapy With Carfilzomib, Lenalidomide, and Dexamethasone Induction (IFM-CRd)

Multiple Myeloma

France
M.D. Anderson Cancer Center
Onyx Therapeutics, Inc.

Terminated

A Phase II Study of Carfilzomib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

Lymphoma

United States
Hackensack Meridian Health
Onyx Therapeutics, Inc.

Completed

A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531

Waldenstrom Macroglobulinemia

United States
ONY

Suspended

Administration of Surfactant Through an Instillation Device Infasurf® (Calfactant) in Neonates- A Pilot Study

Chronic Lung Disease | RDS of Prematurity | Surfactant Protein B Deficiency

United States
ONY

Terminated

Infasurf®(Calfactant) Aerosol for Infants With Bronchiolitis-AERO-04

Bronchiolitis

United States
Omnyx, LLC

Unknown

Evaluation of the Omnyx™ Integrated Digital Pathology System in the Primary Diagnosis of Surgical Pathology Specimens (PrimeDx)

Primary Diagnosis of Surgical Pathology Specimens
AbbVie
Genentech, Inc; Onyx Therapeutics, Inc.

Active, not recruiting

Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)

Multiple Myeloma

United States, Australia, Hungary, Puerto Rico, Spain
University of Arkansas
Onyx Therapeutics, Inc.

No longer available

UARK 2009-32 Compassionate Use Study of Carfilzomib (2009-32)

Multiple Myeloma

United States
ONY

No longer available

Aerosolized Infasurf Treatment Protocol: Aerosolized Infasurf for Spontaneously Breathing Patients With Early RDS (AERO-03)

Neonatal Respiratory Distress

United States
M.D. Anderson Cancer Center
Onyx Therapeutics, Inc.

Completed

Carfilzomib in Refractory Renal Cell Carcinoma (RCC)

Kidney Cancer

United States
Oryx GmbH & Co. KG

Completed

Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme. (ParvOryx01)

Glioblastoma Multiforme

Germany
ONY
Avania

Not yet recruiting

InfasurfAero™ Versus Sham Treatment in Preterm Newborns With RDS (Aero-05)

Intubation Complication | Death; Neonatal | Respiratory Distress Syndrome (Neonatal)

United States
Memorial Sloan Kettering Cancer Center
Celgene; Onyx/Amgen

Active, not recruiting

High Dose Carfilzomib for Newly Diagnosed Myeloma

Multiple Myeloma

United States
SCRI Development Innovations, LLC
Novartis; Onyx Therapeutics, Inc.

Completed

Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States
Oryx GmbH & Co. KG

Completed

Parvovirus H-1 (ParvOryx) in Patients With Metastatic Inoperable Pancreatic Cancer (ParvOryx02)

Carcinoma, Pancreatic Ductal

Germany
Oryx GmbH & Co. KG

Completed

Vaccination Against MSI Colorectal Cancer

Colorectal Cancer

Germany
M.D. Anderson Cancer Center
Celgene; Onyx Therapeutics, Inc.

Terminated

Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

Lymphoma

United States
Oryx GmbH & Co. KG

Completed

Cisplatin-based Chemotherapy Combined With P16_37-63 Peptide Vaccination in Patients With HPV-positive Cancers (VICORYX-2)

HPV-induced Cancers

Germany
Oryx GmbH & Co. KG

Completed

Immune Therapy of HPV-induced Cancers

HPV-induced Cancers

Germany
Beth Israel Deaconess Medical Center
National Cancer Institute (NCI); Bayer; Dana-Farber Cancer Institute; Brigham and... and other collaborators

Completed

Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer

Hepatocellular Cancer

United States
Weill Medical College of Cornell University
Onyx Therapeutics, Inc.

Active, not recruiting

Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma (CarBiRD)

Multiple Myeloma

United States
Bayer

Not yet recruiting

A Study to Learn About How BAY2927088 Affects the Level of Midazolam in the Blood When Both Drugs Are Taken Together in Healthy Participants

Healthy Volunteers | Advanced Non-small Cell Lung Cancer | EGFR Mutation | HER2 Mutation
Bayer

Not yet recruiting

A Study to Learn About How BAY2927088 Affects the Level of Dabigatran or Rosuvastatin in the Blood When These Drugs Are Taken Together in Healthy Participants

Healthy Volunteers | Advanced Non-small Cell Lung Cancer | EGFR Mutation | HER2 Mutation

United Kingdom
Bayer

Recruiting

A Study to Learn More About the Safety of Damoctocog-alfa-pegol When Used in Routine Medical Care in Korean Participants With Hemophilia A

Hemophilia A | Prophylaxis of Bleeding | Treatment of Bleeding

Korea, Republic of
Bayer

Recruiting

First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC) (PAnTHA)

Advanced Metastatic Castration-resistant Prostate Cancer | Prostate Specific Membrane Antigen (PSMA) Expression

Canada, United Kingdom, Belgium
Bayer

Recruiting

An Observational Study to Learn More About the Use of Vericiguat in Korean People With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) in Real-world Setting

Chronic Heart Failure With Reduced Ejection Fraction

Korea, Republic of
Bayer

Recruiting

The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema

Visual Impairment | Neovascular Age-related Macular Degeneration (nAMD) | Diabetic Macula Edema (DME)

Germany, United Kingdom, Canada, Denmark, France, Italy, Saudi Arabia, Switzerland, Australia, Finland, Netherlands, Sweden, Norway, United Arab Emirates, Japan
Bayer

Recruiting

A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Men With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)

Metastatic Castration-resistant Prostate Cancer

United Kingdom, Netherlands, Finland
Bayer

Recruiting

A Study to Learn How Well the Drug Vericiguat Works and How Safe it is Under Real World Conditions in Indian Participants After Worsening of a Long-term Heart Condition in Which the Left Side of the Heart Does Not Pump Blood as Well as it Should (Chronic Heart Failure With Reduced Ejection Fraction)

Chronic Heart Failure With Reduced Ejection Fraction | Worsening Heart Failure

India
Bayer

Recruiting

An Observational Study Called JOIHA to Learn More About How Well the Treatment With Jivi Works to Prevent Problems With Joints in Adults With Hemophilia A (JOIHA)

Hemophilia A | Prophylaxis of Bleeding

Italy
Bayer

Recruiting

A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors

Advanced Solid Tumors

United States, United Kingdom, Korea, Republic of, Japan, Spain, Belgium, China
Bayer

Recruiting

A Study Called SMART-Finder to Look for People With Increased Amounts of Albumin in the Urine (UACR Level) in a Group of Type 2 Diabetes Mellitus Patients (SMART-Finder)

Type 2 Diabetes Mellitus | Chronic Kidney Disease

Germany
Bayer

Recruiting

Investigation of Radium-223 Dichloride (Xofigo), a Treatment That Gives Off Radiation That Helps Kill Cancer Cells, Compared to a Treatment That Inactivates Hormones (New Antihormonal Therapy, NAH) in Patients With Prostate Cancer That Has Spread to the Bone Getting Worse on or After Earlier NAH

Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Hong Kong, Spain, Taiwan, Australia, Turkey, France, Germany, Hungary, United Kingdom, Singapore, Korea, Republic of, Czechia, Italy, Finland, Israel, Austria, Lithuania, Poland, Russian Federation
Bayer

Active, not recruiting

A Study to Learn How Safe the Study Drug BAY 2416964 (AhR Inhibitor) in Combination With the Treatment Pembrolizumab is, How This Combination Affects the Body, the Maximum Amount That Can be Given, How it Moves Into, Through and Out of the Body and Its Action Against Advanced Solid Cancers in Adults

Advanced Solid Tumors

United States, Singapore, Italy, United Kingdom
Bayer

Active, not recruiting

Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A (HEM-POWR)

Hemophilia A

Canada, Japan, Spain, United States, Germany, Sweden, Belgium, Brazil, Greece, Italy, Netherlands, Taiwan, Denmark, Kuwait, Saudi Arabia, United Arab Emirates, Norway, Colombia, Switzerland, Slovenia
Bayer

Completed

A Study to Learn How BAY2927088 is Taken up and Handled by the Body in Healthy Male Participants

Healthy Volunteers | Advanced Non-small Cell Lung Cancer | EGFR Mutation | HER2 Mutation

Netherlands
Bayer

Active, not recruiting

A Study to Learn More About How Safe Dienogest is and How Well it Works Under Real World Conditions in Indian Women With Endometriosis (VISAGE)

Endometriosis Associated Pelvic Pain

India
Bayer

Active, not recruiting

Evaluation of Safety and Effectiveness of the Essure (Model ESS505) Device to Prevent Pregnancy in Women

Contraception

Spain, United States, Netherlands, Canada
Bayer

Active, not recruiting

Non-proliferative Diabetic Retinopathy Treated With Runcaciguat (NEON-NPDR)

Diabetic Retinopathy

United States, Czechia, Denmark, Portugal, Spain, United Kingdom, Netherlands, Bulgaria, Latvia, Slovakia, Germany, Poland, Romania, Switzerland
Bayer

Active, not recruiting

The VERIFY Study: An Observational Study Called VERIFY to Learn More About the Use of Vericiguat in People With Chronic Heart Failure With Reduced Ejection Fraction

Chronic Heart Failure With Reduced Ejection Fraction

Germany
Bayer

Active, not recruiting

A Study Using Available Data to Learn to What Extent Patients With Prostate Cancer Who Received Second Generation Androgen Receptor Inhibitors Took Their Medication as Prescribed or Stopped Taking Their Medication Completely

Prostate Cancer

United States

3

Subscribe